DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Sodium 0.5%
Drug: Carboxymethylcellulose Based Eye Drop

First Posted Date: 2015-09-18

Last Posted Date: 2017-11-17

Lead Sponsor: Allergan

Target Recruit Count: 242

Registration Number: NCT02553772

Locations: 🇺🇸
Havana Research Institute LLC, Burbank, California, United States
🇦🇺
The University of New South Wales School of Optometry and Vision Science, Sydney, Australia
🇺🇸
Lugene Eye Institute, Glendale, California, United States

and more 10 locations

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: Bimatoprost cutaneous solution 0.03%

First Posted Date: 2015-07-22

Last Posted Date: 2018-08-14

Lead Sponsor: Allergan

Target Recruit Count: 1699

Registration Number: NCT02505776

Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®

Completed

Conditions: Migraine Disorders

Interventions: Other: No Intervention

First Posted Date: 2015-07-20

Last Posted Date: 2019-04-05

Lead Sponsor: Allergan

Target Recruit Count: 215

Registration Number: NCT02502123

Locations: 🇨🇦
Toronto Headache & Pain Centre, North York, Ontario, Canada
🇨🇦
Hany Demian, Oakville, Ontario, Canada
🇨🇦
The Shapero Markham Headache and Pain Treatment Centre, Markham, Ontario, Canada

and more 12 locations

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

Phase 2

Completed

Conditions: Hyperhidrosis

Interventions: Biological: Vehicle
Biological: ANT-1207

First Posted Date: 2015-06-24

Last Posted Date: 2017-09-20

Lead Sponsor: Allergan

Target Recruit Count: 145

Registration Number: NCT02479139

Locations: 🇺🇸
Baumann Cosmetic & Research Institute, Miami, Florida, United States
🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States
🇺🇸
Shideler Clinical Research Center, Carmel, Indiana, United States

and more 16 locations

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar Pegol
Drug: Ranibizumab
Other: Sham Procedure

First Posted Date: 2015-06-04

Last Posted Date: 2020-07-30

Lead Sponsor: Allergan

Target Recruit Count: 949

Registration Number: NCT02462486

Locations: 🇺🇸
Paducah Retinal Center, Paducah, Kentucky, United States
🇺🇸
Maculacare - New York, New York, New York, United States
🇺🇸
Retina Vitreous Surgeons of Central NY, PC, Syracuse, New York, United States

and more 184 locations

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar Pegol
Drug: Ranibizumab
Other: Sham Procedure

First Posted Date: 2015-06-04

Last Posted Date: 2020-07-28

Lead Sponsor: Allergan

Target Recruit Count: 939

Registration Number: NCT02462928

Locations: 🇨🇱
Instituto Oftalmologica Profesor Arentsen, Santiago, Región Metropolitana, Chile
🇵🇭
Asian Eye Institute, Makati City, Metro Manila, Philippines
🇵🇭
St. Luke's Medical Center, Quezon City, Metro Manila, Philippines

and more 148 locations

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Sodium Based Eye Drops
Drug: Genteal® Lubricant Gel Drops
Drug: Systane® Gel Drops

First Posted Date: 2015-05-27

Last Posted Date: 2017-01-04

Lead Sponsor: Allergan

Target Recruit Count: 79

Registration Number: NCT02455050

Retrospective Study of Reoperation After Primary Augmentation With NATRELLE® INSPIRA® Breast Implants

Completed

Conditions: Breast Implantation

Interventions: Device: Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants
Device: Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants
Device: Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants

First Posted Date: 2015-05-08

Last Posted Date: 2016-07-25

Lead Sponsor: Allergan

Target Recruit Count: 330

Registration Number: NCT02438332

Locations: 🇨🇦
Macleod Trail Plastic Surgery, Calgary, Alberta, Canada
🇨🇦
Rice Cosmetic Surgery, Toronto, Ontario, Canada
🇨🇦
Ottawa Plastic Surgery: Dr. Howard Silverman, Ottawa, Ontario, Canada

and more 14 locations

Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: AGN-223575 ophthalmic solution
Drug: AGN-223575 vehicle ophthalmic solution

First Posted Date: 2015-05-06

Last Posted Date: 2019-04-05

Lead Sponsor: Allergan

Target Recruit Count: 236

Registration Number: NCT02435914

Locations: 🇺🇸
Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States
🇺🇸
Eye Care Associates of Greater Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Whitsett Vision Group, Houston, Texas, United States

and more 25 locations

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Phase 1

Completed

Conditions: Healthy Volunteers
Dry Eye Syndromes

Interventions: Drug: AGN-232411
Drug: AGN-232411 Vehicle

First Posted Date: 2015-04-20

Last Posted Date: 2016-07-14

Lead Sponsor: Allergan

Target Recruit Count: 77

Registration Number: NCT02420730

Locations: 🇺🇸
Montebello Medical Center, Inc., Montebello, California, United States
🇺🇸
Sall Research Center, Artesia, California, United States
🇺🇸
Lugene Eye Institute, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy